title: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
abstract: OBJECTIVE
  Arthralgia is an adverse class effect of aromatase inhibitors (AIs). To date, its exact mechanism remains unclear. The purpose of this study was to investigate the changes in clinical rheumatologic features and magnetic resonance imaging (MRI) of hands and wrists in AI and tamoxifen users.
  
  
  METHODS
  This is a prospective single-center study including 17 consecutive postmenopausal patients with early breast cancer receiving either tamoxifen (n = 5) or an AI (n = 12). At baseline and after 6 months, patients filled in a rheumatologic history questionnaire and a rheumatologic examination including a grip strength test was done. At the same time points, MRI of both hands and wrists was performed. The primary end point was tenosynovial changes from baseline on MRI. Secondary end points were changes from baseline for morning stiffness, grip strength, and intra-articular fluid on MRI. Wilcoxon signed ranks was used to test changes from baseline and the Spearman correlation coefficient to assess the association between rheumatologic and MRI changes from baseline.
  
  
  RESULTS
  At 6 months, patients on AI had a decrease in grip strength (P = .0049) and an increase in tenosynovial changes (P = .0010). The decrease in grip strength correlated well with the tenosynovial changes on MRI (P = .0074). Only minor changes were seen in patients on tamoxifen. AI users reported worsening of morning stiffness and showed an increase in intra-articular fluid on MRI.
  
  
  CONCLUSIONS
  The functional impairment of hands in the AI-associated arthralgia syndrome is characterized by tenosynovial changes on MRI correlating with a significant decrease in hand grip strength.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
authors.forename: Leilani
authors.initials: L
authors.lastname: Morales
authors.forename: Steven
authors.initials: S
authors.lastname: Pans
authors.forename: Kilian
authors.initials: K
authors.lastname: Verschueren
authors.forename: Ben
authors.initials: B
authors.lastname: Van Calster
authors.forename: Robert
authors.initials: R
authors.lastname: Paridaens
authors.forename: Rene
authors.initials: R
authors.lastname: Westhovens
authors.forename: Dirk
authors.initials: D
authors.lastname: Timmerman
authors.forename: Luc
authors.initials: L
authors.lastname: De Smet
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.forename: Marie-Rose
authors.initials: MR
authors.lastname: Christiaens
authors.forename: Patrick
authors.initials: P
authors.lastname: Neven
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D018771:Arthralgia / Q000139:chemically induced* / Q000175:diagnosis; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D018737:Hand Strength; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017698:Postmenopause; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D013577:Syndrome; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen